Clinical Trials Browser

Phase 1/2 × OTHER × lorlatinib × Clear all

NCT06007937 2026-02-05

A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Recurrence

NCT04292119 2021-03-10

Lorlatinib Combinations in Lung Cancer

Phase 1/2 Unknown

Lung Neoplasms, Recurrence